Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study

Affiliations

• ¹ Center of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China; The International Joint Research Laboratory for Infection and Immunity (China-Germany), Jiangnan University, Wuxi, China; Hepatology Institute of Wuxi, The Fifth People's Hospital of Wuxi (Wuxi Infectious Disease Hospital), Affiliated Hospital of Jiangnan University, Wuxi, China.
• ² Center of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China; The International Joint Research Laboratory for Infection and Immunity (China-Germany), Jiangnan University, Wuxi, China.
• ³ Center of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
• ⁴ Center of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: [email protected].
• ⁵ The International Joint Research Laboratory for Infection and Immunity (China-Germany), Jiangnan University, Wuxi, China; Hepatology Institute of Wuxi, The Fifth People's Hospital of Wuxi (Wuxi Infectious Disease Hospital), Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: [email protected].